Rna Therapeutics Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

RNA therapeutics represent a transformative class of medicines that modulate gene expression, enabling precise intervention in diseases that have historically been difficult to treat with conventional drugs. The global market stands at roughly USD 10.0 billion in 2025 and is forecast to expand at a 13.66% CAGR, reflecting both the maturation of existing RNA platforms and the entry of new modalities into clinical use. Estimates across industry analyses vary widely, from about USD 7.7 billion for narrower mRNA-focused scopes to over USD 20 billion for broader RNA-inclusive definitions, underscoring how segmentation choices materially shape market sizing.

• •Valued at approximately USD 10.0 billion in 2025 with a projected 13.66% CAGR.
• •Covers mRNA, RNAi, ASOs, siRNA, and RNA-based small molecule modulators.
• •Demand is shifting from infectious disease vaccines toward oncology and rare diseases.

The principal growth engine is the accelerating clinical and commercial validation of RNA platforms, demonstrated most visibly by the global deployment of mRNA COVID-19 vaccines, which validated LNP delivery at scale. Expanding pipelines for siRNA and ASO candidates in genetically defined conditions, such as transthyretin amyloidosis, spinal muscular atrophy, and Duchenne muscular dystrophy, are widening the therapeutic footprint of RNA drugs. Concurrently, rising R&D spending by large pharmaceutical companies, growing venture capital inflows into RNA startups, and favorable regulatory pathways for rare disease therapies are accelerating time-to-market.

• •Successful COVID-19 mRNA vaccine deployment validated LNP delivery platforms.
• •Rising incidence of cancer and rare genetic disorders expands the addressable patient pool.
• •Regulatory incentives such as orphan drug and breakthrough therapy designations shorten approval timelines.

By modality, mRNA-based products and vaccines currently account for the largest revenue share, though RNAi and antisense oligonucleotide segments are growing at higher rates due to their precision in silencing disease-causing genes. By application, oncology and rare genetic disorders lead, followed by infectious diseases, with cardiovascular and neurological applications emerging as the next wave of growth. Geographically, North America dominates the market owing to concentrated biotech activity, strong venture financing, and a deep clinical trial infrastructure, while Asia-Pacific is the fastest-growing region as China, South Korea, and Japan scale domestic RNA manufacturing capabilities.

• •North America leads revenue; Asia-Pacific is the fastest-growing regional segment.
• •Oncology and rare genetic disorders represent the largest therapeutic application areas.
• •LNP-enabled mRNA dominates today, while GalNAc-conjugated siRNA is the fastest-rising platform.

What are the recent trends and outlook?

Looking ahead, the market is shifting from vaccine-centric applications toward therapeutic RNA drugs in oncology, neurology, and metabolic disease, with self-amplifying RNA (saRNA) and circular RNA (circRNA) emerging as next-generation platforms that promise lower doses and longer duration of effect. Personalized mRNA cancer vaccines, neoantigen-targeted therapies, and in vivo gene editing using RNA-guided CRISPR systems are advancing rapidly through clinical trials and could redefine treatment paradigms over the next decade. With a 13.66% CAGR, the RNA therapeutics market is on track to potentially exceed USD 20 billion by the early 2030s, supported by improving delivery technologies, expanding manufacturing capacity, and broadening payer acceptance of genetic medicines.

• •Self-amplifying and circular RNA platforms are moving from preclinical into clinical development.
• •Personalized mRNA cancer vaccines represent a major potential growth frontier.
• •With sustained ~13.66% growth, the market could surpass USD 20 billion by the early 2030s.